Clinical Takeaway Transdermal cannabidiol gel (ZYN002) has demonstrated an acceptable long-term safety and tolerability profile in children and adolescents with Fragile X syndrome across an ongoing open-label extension study. The transdermal delivery...
Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
Clinical Takeaway Transdermal cannabidiol gel (ZYN002) has demonstrated an acceptable long-term safety and tolerability profile in children and adolescents with Fragile X syndrome across an ongoing open-label extension study. The treatment targets...
Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
Clinical Takeaway Transdermal cannabidiol gel (ZYN002) has been studied in children and adolescents with Fragile X syndrome through an open-label extension trial focused on long-term safety and tolerability. Early interim data suggest...
Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
Clinical Takeaway Transdermal cannabidiol gel (ZYN002) is being studied in an open-label extension trial to assess its long-term safety and tolerability in children and adolescents with Fragile X syndrome, a condition involving...